A double-blind randomised trial of dapagliflozin versus placebo for myocardial fibrosis on cardiac MRI in 100 patients with type 2 diabetes and HFpEF. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
A small mechanistic study finds exenatide plus glucagon doubles myocardial glucose uptake in type 2 diabetes, a proof-of-concept for cardiac metabolic effects. PICO summary and commentary.
An RCT finds the GLP-1 analogue Ebenatide improves glycaemia, time in range, and body composition in type 2 diabetes, confirming a class effect. PICO summary and commentary.
A small single-centre RCT testing CGM-guided individualised care versus self-monitored blood glucose in 80 pregnant women with diabetes. PICO summary and expert commentary.
An acute crossover infusion study (n=8) found exenatide-glucagon co-infusion raised myocardial glucose uptake and a diastolic strain rate marker in type 2 diabetes. PICO summary and expert commentary.
An open-label randomised trial testing pharmacist-led collaborative care against usual care on EQ-5D quality of life and HbA1c in 400 patients with diabetes. PICO summary and expert commentary.
A small single-blind RCT (n=60) found a family-centered empowerment program raised diabetes acceptance and self-management questionnaire scores versus usual care, with no glycaemic outcomes measured. PICO summary and expert commentary.
A manufacturer-sponsored secondary analysis and propensity-matched real-world dataset suggest the mySugr digital logbook is associated with better glycaemic control, strongest in those with high baseline HbA1c. PICO summary and expert commentary.
A proof-of-concept cluster randomised trial found the INTEGRATE-D implementation support intervention feasible and acceptable in primary care, with mixed effects on process and clinical outcomes. PICO summary and expert commentary.
A randomised waitlist-controlled trial of a 10-week whole-food plant-based community programme in a predominantly Maori cohort: weight fell by 3.3 kg versus control, but HbA1c, cholesterol and waist changes were not significant. PICO summary and expert commentary.